Moderna Inc. (NASDAQ:MRNA) finished Wednesday with a subtraction of -$0.78 to close at $115.46, a downside of -0.67 percent. An average of 6,057,920 shares of common stock have been traded in the last five days. There was a gain of $16.54 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 4,701,260 shares traded, while the 50-day average volume stands at 3,821,268.
MRNA stock has decreased by -5.26% in the last month. The company shares reached their 1-month lowest point of $95.02 on 08/16/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $95.02 and a high of $217.25 in 52 weeks. It has reached a new high 6 times so far this year and lost -35.72% or -$64.16 in price. In spite of this, the price is down -46.85% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
MRNA stock investors should be aware that Moderna Inc. (MRNA) stock had its last reported insider trading activity 7 days ago on Aug 17. In this transaction, the insider spent $1,500,000. Director, AFEYAN NOUBAR, disposed of 10,000 shares at a price of $97.56 on Aug 16. The insider now owns more than $975,614 worth of shares. Prior to that, President Hoge Stephen went on to Sale 247 shares at $102.53 each on Aug 10. An amount of $25,325 was transacted.
Valuation Metrics
Moderna Inc. (MRNA) has a trailing price-to-earnings (P/E) ratio of 42.70. The stock’s beta is 1.61. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.31, the price-to-book (PB) ratio at 2.60.
Financial Health
The quick ratio of Moderna Inc. for the recent quarter was 3.20, and the current ratio was 3.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.05 and a total debt to equity ratio of 0.06 for the recent quarter. Moderna Inc.’s EBITDA margin is 50.31%, while its operating margin for the same period stands at 4.80%. Its gross profit as reported stood at $13.85 billion compared to revenue of $19.26 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Moderna Inc.’s return on assets was 4.90%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$1.38 billion in the quarter, while revenues were grew 259.2%. Shareholders own equity worth $380.59 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Moderna Inc. (MRNA) price momentum. RSI 9-day as of the close on 23 August was 62.27%, suggesting the stock is Neutral, with historical volatility in this time frame at 68.32%.
As of today, MRNA’s price is $110.13 +16.72% or $16.54 from its 5-day moving average. MRNA is currently trading -4.30% lower than its 20-day SMA and -21.69% lower than its 100-day SMA. However, the stock’s current price level is -6.53% below the SMA50 and -21.72% below the SMA200.
The stochastic %K and %D were 89.53% and 70.55%, respectively, and the average true range (ATR) was 5.50. With the 14-day stochastic at 90.20% and the average true range at 5.10, the RSI (14) stands at 55.88%. The stock has reached 8.99 on the 9-day MACD Oscillator while the 14-day reading was at 10.07.
Analyst Ratings
TD Cowen downgraded Moderna Inc. (NASDAQ: MRNA) to a a Market perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Moderna Inc. (MRNA) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell MRNA, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 8 others rate it as a “buy”.
What is MRNA’s price target for the next 12 months?
Analysts predict a range of price targets between $68.00 and $430.00, with a median target of $167.00. Taking a look at these predictions, the average price target given by analysts for Moderna Inc. (MRNA) stock is $180.21.
